GSA Capital Partners LLP Buys Shares of 3,138 BioNTech SE (NASDAQ:BNTX)

GSA Capital Partners LLP purchased a new stake in shares of BioNTech SE (NASDAQ:BNTX) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor purchased 3,138 shares of the company’s stock, valued at approximately $373,000.

Several other large investors have also recently added to or reduced their stakes in the company. Covestor Ltd lifted its stake in BioNTech by 47.2% in the first quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after buying an additional 133 shares during the last quarter. GAMMA Investing LLC lifted its stake in BioNTech by 86.9% in the second quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock valued at $41,000 after buying an additional 238 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in BioNTech by 106.3% in the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after buying an additional 252 shares during the last quarter. Blue Trust Inc. lifted its stake in BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after buying an additional 388 shares during the last quarter. Finally, Daiwa Securities Group Inc. lifted its stake in BioNTech by 430.3% in the second quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company’s stock valued at $155,000 after buying an additional 1,562 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors.

BioNTech Stock Performance

Shares of NASDAQ BNTX opened at $108.20 on Friday. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average is $113.80 and its two-hundred day moving average is $97.56. The company has a market cap of $25.94 billion, a P/E ratio of -51.52 and a beta of 0.26. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. The business had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. BioNTech’s quarterly revenue was up 38.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.73 earnings per share. On average, equities analysts expect that BioNTech SE will post -3.68 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on BNTX. UBS Group raised their price target on BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a report on Wednesday, September 18th. The Goldman Sachs Group raised BioNTech from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $90.00 to $137.00 in a report on Friday, November 8th. Jefferies Financial Group raised BioNTech from a “hold” rating to a “buy” rating and lifted their target price for the stock from $96.00 to $150.00 in a report on Tuesday, September 17th. Canaccord Genuity Group reissued a “buy” rating and issued a $171.00 price target on shares of BioNTech in a research note on Thursday, November 14th. Finally, Evercore ISI raised BioNTech from an “in-line” rating to an “outperform” rating and lifted their price target for the stock from $110.00 to $125.00 in a research note on Tuesday. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $138.79.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.